SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Callisto Pharmaceuticals
An SI Board Since December 2005
Posts SubjectMarks Bans Symbol
19 1 0 KAL
Emcee:  John McCarthy Type:  Unmoderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
19The company has had new releases and seems to be making an effort to move but tiG. Stewart-4/13/2006
18Callisto Outlines Achievements in Development of Anti-Cancer Drug Candidates andJohn McCarthy-12/8/2005
17Press Release Source: Callisto Pharmaceuticals, Inc. Callisto Launches MilestoJohn McCarthy-12/6/2005
16Callisto's CEO Dr. Gary Jacob Discusses Launch of Human Clinical Trial of CaJohn McCarthy-12/6/2005
15Message 21940489Julius Wong-12/3/2005
14About STAT3 - Part 2 1: Oncogene. 2005 Oct 3; [Epub ahead of print] Related ArtJohn McCarthy-12/3/2005
13About STAT3 - Part 1 Note: Did a search on STAT3 and Cancer. Decided this abstJohn McCarthy-12/3/2005
122005 - Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple John McCarthy-12/3/2005
111999 - SK&F 106615 (atiprimod). 1: Toxicol Appl Pharmacol. 1999 Aug 15;159John McCarthy-12/3/2005
101999 - Atiprimod (SK&F 106615) 1: Int J Immunopharmacol. 1999 Mar;21(3):161John McCarthy-12/3/2005
91998 - SK&F 106615 Inflamm Res. 1998 Feb;47(2):56-61. Related Articles, LiJohn McCarthy-12/3/2005
81997 - SK&F 106615 1: Immunopharmacology. 1997 Aug;37(1):53-61. Related ArtJohn McCarthy-12/3/2005
72000 - Atiprimod (AnorMED). Lakings DB. Drug Safety Evaluation Consulting Inc,John McCarthy-12/3/2005
62004 - Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis. John McCarthy-12/3/2005
52005 - Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanaminJohn McCarthy-12/3/2005
41999 - Int J Immunopharmacol. 1999 Mar;21(3):161-76. Related Articles, Links John McCarthy-12/3/2005
3News Release from: Callisto Pharmaceuticals Edited by the Laboratorytalk EditorJohn McCarthy-12/3/2005
2[111] A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients wJohn McCarthy-12/3/2005
1[249] In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple MyelJohn McCarthy-12/3/2005
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News